Individualized Management of Patients With Glaucoma: How The -

Name: Individualized Management of Patients With Glaucoma: How Therapeutic Advances Will Improve Patient Care Web 1
Uploaded: 2018-06-26T08:00:00+00:00
Duration: 1 h 10 min 12 s
Description: Supported through an educational grant from Aerie Pharmaceuticals.

Media formats available:

Details

Presenters

Overview
Supported through an educational grant from Aerie Pharmaceuticals.
Learning Objectives
Learning Objectives Upon completion of this activity, the participant should be able to: • Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications • Explain the anti-fibrotic activity in novel drug classes • Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance
Accreditation
Accreditation Statement Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hours of CE Credit for Optometrists COPE Course ID: 58456-GL COPE Event ID: 115763
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Thomas Samuelson, MD Minnesota Eye Consultants Adjunct Professor University of Minnesota Minneapolis, MN Douglas Rhee, MD Case Western Reserve University Department Chair University Hospitals Department of Ophthalmology and Visual Sciences Cleveland, Ohio The following faculty/staff members have the following financial relationships with commercial interests: Thomas Samuelson, MD; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AcuMEMS; Aerie Pharmaceuticals; Akorn; Alcon Surgical; AMO (Abbott Medical Optics) AqueSys; Bausch and Lomb; BELKIN Laser; Endo Optics; Equinox; Glaukos Corporation; and Ivantis; Ocular Surgery News; PolyActiva, Santen Pharmaceutical Co, Ltd; Shire Plc; Transcend Medical, Veracity Innovations, LLC; and Vindico/Slack. Stock Options: Equinox; Glaukos Corporation; and Ivantis. Douglas Rhee, MD; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals. Speakers Bureau: Bausch and Lomb; Grant/Research Support: Allergan plc, Glaukos Corporation, and Ivantis.
Disclaimer
Off-Label Statement This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Aerie Pharmaceuticals.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 06/26/2018
Expiration Date: 06/19/2019